Highest development stage: Phase 1

Development status: Inactive

Combination therapy: Was tested with pipercillin in murine modelswhich demonstrated a similar level of efficacy as pipercillin:tazobactam

Mechanism of Action/Target pathogen: β-lactamase inhibitor, inhibits class A, C and D β-lactamases

Reason dropped: Was in phase I trials with Wyeth, however, with Pfizer (purchased Wyeth in 2009) closed it's antibioitc research unit in 2011 (1,2).